• The MMWR study details the discovery of Schedule I drugs, including psilocybin and psilocin, in nootropic gummies that were sold in Virginia between late 2023 and early 2024 and contained Amanita muscaria or other mushrooms.

• After consuming these gummies, tachycardia, confusion, and nausea were reported by five individuals, one of whom was a youngster.

• According to laboratory testing, these candies also had additional ingredients like caffeine, ephedrine, and mitragynine.

• Because customers are unaware that these chemicals could cause severe sickness, their presence risks public health.

• Healthcare professionals and the general public are advised by the report to exercise caution while using nootropics that contain mushrooms because they may contain hazardous and hidden components.

• It is advised that anyone having symptoms after consumption seek medical assistance right once.

Click here to read more.